KKR closes $5.9B Integer Holdings takeout as healthcare carries August PE volume

KKR & Co. closed its $5.89 billion acquisition of Integer Holdings on August 29, marking the firm's largest healthcare transaction of the year and representing roughly one-fifth of all healthcare private equity volume for the month. The medical device manufacturer, which supplies cardiac rhythm management and neuromodulation components to Medtronic and Abbott, transitioned from NYSE listing to KKR portfolio company without filing extensions or renegotiating price.

Global private equity dealmaking fell 31 percent month-over-month in August to $89 billion across 847 transactions, according to Refinitiv data. Healthcare absorbed $28.4 billion of that total, a 42 percent sector concentration ratio not seen since the pandemic equipment rush of early 2021. KKR's Integer acquisition alone constituted 21 percent of August healthcare PE volume. The close followed a July announcement at $102.50 per share, a 23 percent premium to Integer's thirty-day volume-weighted average price. No financing delays materialized despite the firm's reliance on $3.2 billion in leveraged loan commitments from JPMorgan and Bank of America, both of which syndicated without haircuts in a credit market that has turned selective on anything outside software and healthcare.

Integer's appeal lies in its role as a sole-source supplier for mission-critical implantable components. The company manufactures battery assemblies and hermetic sealing systems that OEMs cannot easily replicate in-house due to FDA qualification timelines running eighteen to twenty-four months. KKR paid 14.2 times Integer's trailing twelve-month EBITDA of $415 million, a multiple that looks rich against the 11.8 times median for industrial components but lands in line with medical technology peers carrying similar regulatory moats. The firm telegraphed plans to expand Integer's neuromodulation and structural heart product lines, two categories where device volume is growing at 9 percent and 12 percent annually, respectively, versus 4 percent for the broader medical device market.

The transaction underscores a bifurcation in private equity appetite. Healthcare dealmaking remained resilient in August while software, industrials, and consumer discretionary saw combined volume drop 47 percent from July levels. Three factors explain the divergence: healthcare assets carry contracted revenue with visible multiyear growth, regulatory barriers limit new competition, and an aging demographic in developed markets creates non-cyclical demand that doesn't correlate with rate-cut timing or election cycles. KKR has deployed $11.3 billion into healthcare since January 2023, more than any other sector in its portfolio, with Integer joining earlier acquisitions of Cotiviti and Envision Physician Services.

Allocators should monitor KKR's debt refinancing calendar in Q1 2025, when the firm will likely move to term out Integer's bridge facilities into permanent capital structure. Watch for margin expansion targets in Integer's investor presentations, particularly around the neuromodulation segment, where the company has lagged Boston Scientific in manufacturing efficiency. The firm's ability to cross-sell Integer components into its existing healthcare portfolio companies—KKR owns ambulatory surgery center operator Surgery Partners and contract research organization Parexel—will signal whether the thesis extends beyond financial engineering. Broader healthcare PE activity faces a test in September, when three pending medtech deals worth a combined $7.1 billion are scheduled to close, including Permira's acquisition of Medline's international division.

Integer's sales pipeline includes $680 million in contracted backlog extending through 2026, most of it tied to Medtronic's next-generation pacemaker platform launches expected in Q2 2025.